nivolumab,ipilimumab,sunitinib,pazopanib
novartis,bms,pfizer
['rcc,(-irccs),(-srcc),(-urcc)', '#607', 'renal,(-adrenal)', 'biomarker', 'nivo', 'bionikk', 'marker ']
excellent session with md yann vano about overall survival and efficacy results of second-line treatment in patients with mrccc treated in the randomized phase ii trial for the first-time overall survival and l2 efficacy results #ascogu23 
Medical Oncologist at Centro Oncológico Integral, Hospital Ángeles Puebla. Cancer treatment must be personalized to the individual needs of the patient.